At the news
? NEUTRALIMPACT 5/10 SC 13D filed Nov 10, 2026 at 18:20 ET
Fivespan Partners filed a Schedule 13D disclosing a 5.3% stake in Stride (LRN) as of November 3, 2026, with 2,236,033 shares held via Fivespan Fund. The filing formalizes an existing Cooperation Agreement (October 8, 2026) that ended a proxy contest, placed Fivespan founder Dylan Haggart on the board, and created a Capital Allocation Committee. The activist has been actively trading around the stake, selling 382,529 shares on October 19-20 and then repurchasing over 1 million shares from October 21 through November 5, suggesting a strategic repositioning after the cooperation deal was in place.
- Fivespan Partners disclosed beneficial ownership of 2,236,033 shares of Stride common stock, representing 5.3% of shares outstanding as of November 3, 2026.
- The stake is held through Fivespan Partners Fund, Ltd. and was acquired for approximately $178.7 million using working capital.
- A Cooperation Agreement signed October 8, 2026 ended Fivespan's proxy contest and Section 220 demand, appointing Dylan Haggart to the board and Dr. Steven Guttentag as a non-voting observer (to become a director after the 2026 annual meeting).
- The agreement created a Capital Allocation Committee co-chaired by Haggart and director Brian Shepherd, with a mandate to review capital structure and allocation strategy.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access